Company intelligence / Profile preview

Immunotope

Doylestown, Pennsylvania, United Statesimmunotope.com ↗

Ownership: Private
Development stage: Other

Overview

Immunotope developed a proprietary immunoproteomics technology to identify disease-specific antigens presented by MHC molecules. Its lead product, IMT‑1012, a multivalent therapeutic vaccine targeting advanced-stage ovarian and breast cancers, completed a Phase 1 trial at Duke University Comprehensive Cancer Center. Other pipeline programs targeted various cancers and chronic viral infections but had not reached late-stage clinical development as of the latest public information before acquisition by ImmunoVaccine Technologies Inc.

Therapeutic areas: Infectious DiseasesOncology
Modalities: VaccineProteinPeptides
Industry: Biotech

Drug pipeline

1 asset

IMT-1012

Partnerships

Midatech Group Ltd.Duke University Comprehensive Cancer Center

Beyond the preview

Go deeper on Immunotope.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunotope.

Explore the full profile